08:48 EDT Nektar (NKTR) jumps 130% to $21.90 after atopic dermatitis study success
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics Announces Positive Phase 2b Trial Results
- Nektar’s rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial
- Closing Bell Movers: Futures up on Iran/Israel truce, KB Home slips on outlook
- Nektar to announce induction period in REZOLVE-AD study of Rezpegaldesleukin
- Upcoming Stock Splits This Week (June 9 to June 13) – Stay Invested